<div id="readability-page-1" class="page"><h3>Claim 30% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Sinopharm Group Co ( (HK:1099) ) has provided an update. Sinopharm Group Co. Ltd., a leading pharmaceutical distributor and healthcare services provider in China, has announced a proposed final cash dividend of RMB 0.69 per share for the financial year ended 31 December 2025. The dividend, to be paid in Hong Kong dollars with the exact amount and exchange rate to be announced, underscores the group’s ongoing profitability and commitment to returning cash to shareholders. The payout is subject to shareholder approval on 18 June 2026, with an ex-dividend date of 23 June, a record date of 30 June, and payment scheduled for 18 August 2026. The company has detailed withholding tax arrangements for different categories of non-resident enterprise and individual shareholders, as well as mainland investors using Stock Connect, which will affect net dividend receipts and is important for investors’ tax planning and after-tax yield expectations. The most recent analyst rating on (HK:1099) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page. More about Sinopharm Group Co Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical distributor and healthcare services provider, listed in Hong Kong. The company focuses on the distribution of medicines and medical products, supporting hospitals, pharmacies, and other healthcare institutions across mainland China and international markets. YTD Price Performance: 7.30% Average Trading Volume: 5,313,248 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$65.1B For an in-depth examination of 1099 stock, go to TipRanks’ Overview page.</div>

000028

01069

01099

Sinopharm Group Co. Ltd. has proposed a final cash dividend of RMB 0.69 per share for the financial year ending December 31, 2025. The dividend is subject to shareholder approval on June 18, 2026, with an ex-dividend date of June 23 and payment scheduled for August 18, 2026. The company has outlined tax arrangements for non-resident shareholders, which will impact net dividend receipts. The latest analyst rating for Sinopharm stock (HK:1099) is a Buy, with a price target of HK$23.00.

Tip Ranks

Sinopharm Accord

CN HEALTH TECH

SINOPHARM

SINOPHARM(CNCM LTD)

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal 800 Health Care ETF

ChinaAMC CSI All Share Health Care Devices ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

Huaan Hang Seng Biotech ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

E Fund CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Sinopharm Proposes Final Cash Dividend of RMB 0.69 per Share for 2025